AB Science annonce l’achèvement de l’étape 3 de la phase 1, évaluant la combinaison d’AB8939 et du vénétoclax dans le traitement de la LMA réfractaire ou en rechute

AB Science reported completion of Phase 1 Step 3 for AB8939 + venetoclax in relapsed/refractory AML, with 4/6 objective responders yielding an ORR of 67% and a DCR of 100% after a single 14-day cycle. The combination was well tolerated with no dose-limiting toxicity observed, enabling selection of the RP2D of AB8939 (16 mg/m² and 21.3 mg/m² cohorts both dosed with venetoclax). The next catalyst is Phase 1 Step 4 evaluating AB8939 + venetoclax + azacitidine.

Analysis

This is less a product-readthrough than a financing/optionality event. The only economically relevant signal is whether a venetoclax-resistant, genomically ugly AML subset can be made meaningfully re-treatable; if that holds up, ABSCF gains partnering leverage and can argue for a differentiated salvage niche, while the broader venetoclax franchise is less threatened than extended because the combo could actually prolong its utility in harder disease.

Near term, the stock reaction should be driven by reflexive biotech flows, but the data are too small to support a durable fundamental re-rate without reproducibility in the extension cohort. The real catalyst path is 1-3 months: cohort expansion, any signal on count recovery/durability, and whether management can avoid a dilutive raise before the next readout. Over 6-18 months, the value hinges on whether this becomes a credible registration path or just another phase 1 orphan oncology story.

Contrarian view: the market may be over-anchoring on the lack of dose-limiting toxicity and underweighting selection bias. Six patients, one cycle, and a highly enriched biology do not tell us anything about commercial scale, and any hint that the response rate normalizes downward in the extension cohort would likely compress the stock back to cash-value dynamics. The key falsifier is either emergent marrow toxicity at the selected dose or a sub-30% response rate in the next ~15 patients, especially if accompanied by a financing announcement.

Key Decisions for Investors

• ABSCF: do not chase the opening spike; prefer to wait for a 2-3 day retracement and only buy if volume stays elevated and the company does not announce near-term financing risk. Risk/reward is acceptable only as a trading position, not a core fundamental long.
• If liquidity/borrow allows, pair long ABSCF vs short IBB on a 1-3 month horizon as a catalyst-driven idiosyncratic trade. Thesis: ABSCF can outperform on orphan-oncology optionality while the index gives you cleaner beta neutralization; cut if the extension cohort disappoints or if a dilutive raise hits first.
• Set a hard alert for the extension cohort readout (~15 patients) and treat it as the real decision point: stay long only if ORR remains clearly above historical salvage benchmarks and no new hematologic toxicity appears. If ORR falls below ~30% or DLT emerges, exit immediately.
• Watch for partnership language or EMA/FDA interaction updates rather than the science slide deck. A credible ex-EU partnering term sheet would be the best medium-term upside catalyst; absent that, assume the valuation reverts toward cash and keep position size small.